tirzepatide vs semaglutide microdose for Microdosing Microdosing GLP-1 and GLP-2 medications

The frequency of antiexenatide antibodies and injection site problems were more common with exenatide LAR than with exenatide [17]

An open question remains whether chronic use of GLP1RAs will result in tachyphylaxis of the gastric slowing effect, which will mitigate the risk of DDI [51,52,53]

Simultaneously, the patent cliff hits hard, with generic rivals for Eliquis and other key products causing over $15 billion in annual revenue loss

Advancements in drug formulations, synergistic combinations with other antidiabetic medications, and improved safety profiles are poised to drive market expansion during the forecast period